2016-03-11T00:00:00.000-05:00
blood cancer indications,-0.644356
forward-looking statement,-0.451357
innovative targeted payload,0.49842
York-based biopharmaceutical company,0.619818
durable complete remission,0.491497
chronic lymphocytic leukemia,-0.542004
immediate future,0.325332
Orphan Medicinal Products,-0.418848
advanced cancers,0.49842
murine monoclonal antibody,0.214233
acute lymphoblastic leukemia,-0.327179
acute myeloid leukemia,-0.369073
biopharmaceutical company,0.49842
niche patient population,-0.415479
actual results,-0.377704
white blood cells,-0.644356
preliminary documentation,0.287598
Cancer Research Center,-0.413065
orphan designation,-0.0561407
application form,0.287598
payload immunotherapeutics,0.49842
orphan medicines designation,-0.453778
hematopoietic stem cell,-0.644356
relapsed AML patients,0.491497
refractory Acute Myeloid,-0.415479
chronic myeloid leukemia,-0.508148
forward-looking statements,0.297542
EU orphan designation,0.250426
